Adm1n: Created page with "JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman's team as a hybrid between the dibenzopyran "classical" cannabinoid drugs and the novel ind..."

2015-02-16T14:22:02Z

Created page with "JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman's team as a hybrid between the dibenzopyran "classical" cannabinoid drugs and the novel ind..."

New page

JWH-161 is a cannabinoid derivative that was designed by Dr [[John W. Huffman]]'s team as a hybrid between the dibenzopyran "classical" [[cannabinoid]] drugs and the novel indole derivatives, in an attempt to unravel the differences in their binding modes to the [[CB1]] receptor. While retaining structural elements from both families, JWH-161 has a CB1 Ki of 19.0nM, although it was found to be slightly weaker than [[THC]] in animal tests

JWH-161 - Revision history

Adm1n: Created page with "JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman's team as a hybrid between the dibenzopyran "classical" cannabinoid drugs and the novel ind..."